Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11638601 | 0.91 | CYP2B6 (0.50) | CYP2B6CHRM2CHRM1CYP2D6LMNA | |
| SCHEMBL5139721 | 0.82 | OPRD1 (0.49) | CYP2B6CHRM2CHRM1CYP2D6LMNA | |
| SCHEMBL11541847 | 0.82 | SMN1; SMN2 (0.54) | CYP2B6CYP2D6LMNAOPRM1MEN1 | |
| SCHEMBL4437324 | 0.81 | CHRM3 (0.50) | CYP2B6CHRM2CHRM1CYP2D6LMNA | |
| SCHEMBL15546036 | 0.79 | CYP2B6 (0.43) | CYP2B6KCNH2L3MBTL1 | |
| SCHEMBL2423921 | 0.78 | CYP2B6 (0.55) | CYP2B6CHRM2CHRM1CYP2D6LMNA | |
| SCHEMBL25772069 | 0.78 | CYP2B6 (0.55) | CYP2B6CHRM2CHRM1CYP2D6LMNA | |
| SCHEMBL17810248 | 0.78 | CYP2B6 (0.67) | CYP2B6CHRM2CHRM1CYP2D6LMNA | |
| SCHEMBL19011533 | 0.78 | CYP2B6 (0.96) | CYP2B6CHRM2CHRM1CYP2D6LMNA | |
| SCHEMBL16079079 | 0.77 | DRD2 (0.51) | CHRM2CHRM1CYP2D6LMNAHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186104-A1 | Novel pyridinone and related heterocyclic derivatives | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | US | disclosed |
| EP-1387829-A1 | NOVEL PYRIDINONE AND RELATED HETEROCYCLIC DERIVATIVES | AstraZeneca AB (SE) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002090333-A1 | NOVEL PYRIDINONE AND RELATED HETEROCYCLIC DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186104-A1 | Novel pyridinone and related heterocyclic derivatives | CBR1, CBR3, CHRM1 | CYP2B6 6/4885CHRM2 11/4885CHRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.